Alnylam Pharmaceuticals’ (ALNY) Neutral Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their neutral rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research report sent to investors on Monday, Benzinga reports. Cantor Fitzgerald currently has a $220.00 target price on the biopharmaceutical company’s stock.

Several other analysts also recently weighed in on ALNY. HC Wainwright reaffirmed a buy rating and set a $400.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, August 30th. The Goldman Sachs Group raised shares of Alnylam Pharmaceuticals from a neutral rating to a buy rating and upped their price objective for the stock from $198.00 to $370.00 in a report on Friday, August 16th. Morgan Stanley raised their target price on shares of Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the company an equal weight rating in a research note on Friday, July 12th. TD Cowen upped their price target on shares of Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the stock a buy rating in a research note on Tuesday, June 25th. Finally, Royal Bank of Canada reiterated an outperform rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, September 4th. Seven research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of Moderate Buy and an average target price of $279.14.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $253.16 on Monday. The firm has a fifty day moving average of $257.55 and a 200-day moving average of $192.17. The company has a market cap of $32.50 billion, a price-to-earnings ratio of -94.46 and a beta of 0.38. Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $287.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.61. The firm had revenue of $659.83 million for the quarter, compared to analyst estimates of $447.22 million. During the same period in the previous year, the firm earned ($2.21) earnings per share. The company’s revenue for the quarter was up 107.0% on a year-over-year basis. Analysts predict that Alnylam Pharmaceuticals will post -2.78 EPS for the current year.

Insider Activity

In other news, Director David E. I. Pyott sold 32,450 shares of the stock in a transaction on Monday, June 24th. The shares were sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the transaction, the director now owns 136 shares in the company, valued at approximately $30,013.84. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, Director Dennis A. Ausiello sold 20,250 shares of the company’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the transaction, the director now owns 136 shares in the company, valued at approximately $35,632. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director David E. I. Pyott sold 32,450 shares of the company’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $220.69, for a total value of $7,161,390.50. Following the completion of the sale, the director now owns 136 shares of the company’s stock, valued at approximately $30,013.84. The disclosure for this sale can be found here. Insiders have sold 103,148 shares of company stock worth $25,658,824 in the last 90 days. Company insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Souders Financial Advisors lifted its stake in shares of Alnylam Pharmaceuticals by 1.0% in the 2nd quarter. Souders Financial Advisors now owns 3,512 shares of the biopharmaceutical company’s stock valued at $853,000 after acquiring an additional 36 shares during the last quarter. V Square Quantitative Management LLC lifted its position in Alnylam Pharmaceuticals by 21.9% in the 2nd quarter. V Square Quantitative Management LLC now owns 334 shares of the biopharmaceutical company’s stock valued at $81,000 after acquiring an additional 60 shares in the last quarter. Commerce Bank lifted its position in Alnylam Pharmaceuticals by 1.7% in the 4th quarter. Commerce Bank now owns 4,683 shares of the biopharmaceutical company’s stock valued at $896,000 after acquiring an additional 77 shares in the last quarter. Envestnet Portfolio Solutions Inc. lifted its position in Alnylam Pharmaceuticals by 7.0% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 1,368 shares of the biopharmaceutical company’s stock valued at $262,000 after acquiring an additional 89 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Alnylam Pharmaceuticals by 54.2% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 259 shares of the biopharmaceutical company’s stock worth $63,000 after buying an additional 91 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.